China Aoxing Pharmaceutical Company, Inc., a pharmaceutical company located in China specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products, announced this morning that it has received renewal of the Good Manufacturing Practice (GMP) certification for its capsule formulation and packaging production facility. The certificate of compliance was issued after a site inspection by the State Food and Drug Administration (SFDA).
GMP compliance guarantees that pharmaceuticals, active ingredients and medical devices are manufactured and quality-controlled in accordance with state-of-the-art standards. According to the National Medicine Administration Law of the People’s Republic of China, all pharmaceutical manufacturers must pass an inspection every five years to renew their GMP Certificates.
“GMP compliance is the gold standard in quality assurance in the life science industry. We are happy to obtain the renewal of the GMP certificate for capsule products,” stated Juan Yue Han, Chairman and the CEO of China Aoxing. “This provides the foundation for the further development of China Aoxing. We are well positioned to manufacture pharmaceutical products in capsule dosage form to address significantly unmet medical needs in the areas of cancer pain, acute and chronic pain, as well as other neurological disorders.”